Serum thrombomodulin. A novel marker of disease activity in systemic lupus erythematosus. 1994

M W Boehme, and P P Nawroth, and E Kling, and J Lin, and J Amiral, and J Riedesel, and U Raeth, and W A Scherbaum
Department of Internal Medicine IV, University of Heidelberg, Germany.

OBJECTIVE Soluble thrombomodulin (sTM), a proposed serum marker of endothelial cell injury, was investigated as a parameter of disease activity in patients with systemic lupus erythematosus (SLE). METHODS Levels of sTM were determined by enzyme-linked immunosorbent assay. Disease activity was assessed using 3 established scoring systems: the American College of Rheumatology (ACR), the New York Hospital for Special Surgery (NYHSS), and the Systemic Lupus Activity Measure (SLAM) systems. RESULTS A close correlation was found between sTM levels and disease activity as assessed with all 3 scoring systems: r = 0.52 by the ACR, 0.75 by the NYHSS, and 0.82 by the SLAM. CONCLUSIONS We found that sTM is a sensitive serologic marker of organ involvement in patients with SLE. Furthermore, sTM may prove to be an important marker for vasculitis in general.

UI MeSH Term Description Entries
D008180 Lupus Erythematosus, Systemic A chronic, relapsing, inflammatory, and often febrile multisystemic disorder of connective tissue, characterized principally by involvement of the skin, joints, kidneys, and serosal membranes. It is of unknown etiology, but is thought to represent a failure of the regulatory mechanisms of the autoimmune system. The disease is marked by a wide range of system dysfunctions, an elevated erythrocyte sedimentation rate, and the formation of LE cells in the blood or bone marrow. Libman-Sacks Disease,Lupus Erythematosus Disseminatus,Systemic Lupus Erythematosus,Disease, Libman-Sacks,Libman Sacks Disease
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000293 Adolescent A person 13 to 18 years of age. Adolescence,Youth,Adolescents,Adolescents, Female,Adolescents, Male,Teenagers,Teens,Adolescent, Female,Adolescent, Male,Female Adolescent,Female Adolescents,Male Adolescent,Male Adolescents,Teen,Teenager,Youths
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D012720 Severity of Illness Index Levels within a diagnostic group which are established by various measurement criteria applied to the seriousness of a patient's disorder. Illness Index Severities,Illness Index Severity
D014657 Vasculitis Inflammation of any one of the blood vessels, including the ARTERIES; VEINS; and rest of the vasculature system in the body. Angiitis,Angiitides,Vasculitides
D015415 Biomarkers Measurable and quantifiable biological parameters (e.g., specific enzyme concentration, specific hormone concentration, specific gene phenotype distribution in a population, presence of biological substances) which serve as indices for health- and physiology-related assessments, such as disease risk, psychiatric disorders, ENVIRONMENTAL EXPOSURE and its effects, disease diagnosis; METABOLIC PROCESSES; SUBSTANCE ABUSE; PREGNANCY; cell line development; EPIDEMIOLOGIC STUDIES; etc. Biochemical Markers,Biological Markers,Biomarker,Clinical Markers,Immunologic Markers,Laboratory Markers,Markers, Biochemical,Markers, Biological,Markers, Clinical,Markers, Immunologic,Markers, Laboratory,Markers, Serum,Markers, Surrogate,Markers, Viral,Serum Markers,Surrogate Markers,Viral Markers,Biochemical Marker,Biologic Marker,Biologic Markers,Clinical Marker,Immune Marker,Immune Markers,Immunologic Marker,Laboratory Marker,Marker, Biochemical,Marker, Biological,Marker, Clinical,Marker, Immunologic,Marker, Laboratory,Marker, Serum,Marker, Surrogate,Serum Marker,Surrogate End Point,Surrogate End Points,Surrogate Endpoint,Surrogate Endpoints,Surrogate Marker,Viral Marker,Biological Marker,End Point, Surrogate,End Points, Surrogate,Endpoint, Surrogate,Endpoints, Surrogate,Marker, Biologic,Marker, Immune,Marker, Viral,Markers, Biologic,Markers, Immune

Related Publications

M W Boehme, and P P Nawroth, and E Kling, and J Lin, and J Amiral, and J Riedesel, and U Raeth, and W A Scherbaum
October 1994, Presse medicale (Paris, France : 1983),
M W Boehme, and P P Nawroth, and E Kling, and J Lin, and J Amiral, and J Riedesel, and U Raeth, and W A Scherbaum
January 2000, Clinical and experimental immunology,
M W Boehme, and P P Nawroth, and E Kling, and J Lin, and J Amiral, and J Riedesel, and U Raeth, and W A Scherbaum
August 2010, The Journal of rheumatology,
M W Boehme, and P P Nawroth, and E Kling, and J Lin, and J Amiral, and J Riedesel, and U Raeth, and W A Scherbaum
April 2001, Rheumatology international,
M W Boehme, and P P Nawroth, and E Kling, and J Lin, and J Amiral, and J Riedesel, and U Raeth, and W A Scherbaum
June 2004, Pediatric allergy and immunology : official publication of the European Society of Pediatric Allergy and Immunology,
M W Boehme, and P P Nawroth, and E Kling, and J Lin, and J Amiral, and J Riedesel, and U Raeth, and W A Scherbaum
May 2015, Clinical rheumatology,
M W Boehme, and P P Nawroth, and E Kling, and J Lin, and J Amiral, and J Riedesel, and U Raeth, and W A Scherbaum
January 1986, Scandinavian journal of rheumatology,
M W Boehme, and P P Nawroth, and E Kling, and J Lin, and J Amiral, and J Riedesel, and U Raeth, and W A Scherbaum
January 1991, Clinical and experimental rheumatology,
M W Boehme, and P P Nawroth, and E Kling, and J Lin, and J Amiral, and J Riedesel, and U Raeth, and W A Scherbaum
December 2021, BMC immunology,
M W Boehme, and P P Nawroth, and E Kling, and J Lin, and J Amiral, and J Riedesel, and U Raeth, and W A Scherbaum
December 1999, The Indian journal of medical research,
Copied contents to your clipboard!